Equities

United Laboratories International Holdings Ltd

United Laboratories International Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)10.14
  • Today's Change-0.04 / -0.39%
  • Shares traded6.12m
  • 1 Year change+56.00%
  • Beta0.5605
Data delayed at least 15 minutes, as of May 07 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.

  • Revenue in HKD (TTM)14.82bn
  • Net income in HKD2.91bn
  • Incorporated--
  • Employees15.00k
  • Location
    United Laboratories International Holdings Ltd6 FuK Wang StreetYuen Long Industrial EstateYuen Long Hong KongHKG
  • Phone+852 26871033
  • Fax+852 26871031
  • Websitehttp://www.tul.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
InnoCare Pharma Ltd796.72m-681.00m10.23bn1.09k--1.17--12.84-0.4038-0.40380.47214.370.0731.393.39731,608.40-6.38-13.41-8.08-15.3682.6185.99-87.42-172.164.13--0.1582--18.09240.3628.80--66.20--
AIM Vaccine Co Ltd1.28bn-1.40bn10.35bn1.62k--2.63--8.08-1.16-1.161.063.24------788,805.90--------75.88---164.24--0.7583-14.040.3158---6.06---307.07------
Yichang Hec Changjiang Pharmactcl Co Ltd6.79bn2.15bn11.14bn4.62k5.181.304.591.642.442.447.729.730.51113.624.091,470,441.0015.078.0324.4611.8179.2179.9729.4820.801.3011.160.247515.8168.0820.182,501.2416.15-11.50--
Luye Pharma Group Ltd6.63bn574.57m11.25bn5.27k19.480.8328.401.700.15350.15351.783.590.2472.423.601,257,505.002.172.803.564.4568.4470.538.7810.391.213.100.393111.822.703.50-11.94-16.39-14.05--
SciClone Pharmaceuticals (Holdings) Ltd3.40bn1.21bn11.34bn1.05k9.723.2114.843.331.861.865.235.620.75853.563.833,242,118.0026.9727.0933.3436.3274.6776.0635.5535.434.5027.950.01--14.7617.5031.1615.96----
Zai Lab Ltd2.08bn-2.61bn13.14bn2.18k--2.07--6.31-2.70-2.702.166.400.23642.515.38---29.66-37.72-34.97-42.7264.0864.75-125.46-282.444.41--0.00--24.03360.0324.51---3.45--
SSY Group Ltd6.46bn1.32bn14.40bn5.60k10.962.088.242.230.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
Simcere Pharmaceutical Group Ltd7.13bn771.07m14.88bn7.03k19.711.9113.472.090.28930.28932.732.980.61063.532.651,014,429.006.6010.178.9415.6075.4378.8210.8017.501.870.97420.165246.684.497.92-23.22-0.521323.93--
Grand Pharmaceutical Group Ltd10.53bn1.88bn15.90bn10.53k8.361.036.951.510.53560.53563.004.330.46922.9410.26999,581.408.4510.0911.6614.0161.9661.9718.0022.350.981922.960.183126.9410.1212.06-9.5921.415.6924.77
3SBio Inc8.43bn1.67bn16.07bn5.41k9.781.047.761.910.67360.67363.456.310.34261.587.011,558,253.006.957.449.039.2984.9882.9120.3021.502.2622.720.2266--13.8411.26-19.133.948.78--
The United Laboratories Intl. Hldgs Ltd.14.82bn2.91bn18.50bn15.00k6.351.355.251.251.601.608.167.560.68713.366.15988,156.9013.517.8920.5212.6446.1144.1719.6612.731.74--0.105528.9921.2212.8470.8531.6624.1914.67
China Traditional Chinese Med Hldg CoLtd19.55bn1.39bn21.65bn17.30k15.620.94868.031.110.27530.27533.884.530.49851.472.161,129,837.003.844.605.857.0751.1857.077.709.771.489.830.177317.3526.699.9968.11-2.24-12.75--
WuXi XDC Cayman Inc2.29bn305.88m25.03bn1.18k74.764.2567.7110.920.27960.27962.134.91------1,944,960.00--------26.35--13.35--4.03--0.0005--114.44--82.07------
Genscript Biotech Corp6.56bn-745.72m26.38bn6.94k--2.42--4.02-0.354-0.3543.115.120.2837.595.45945,241.60-11.97-18.34-18.27-26.1548.7854.68-42.30-64.914.65--0.1694--34.1729.4457.91--17.14--
Data as of May 07 2024. Currency figures normalised to United Laboratories International Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.64%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Apr 202434.80m1.92%
Dimensional Fund Advisors LPas of 04 Apr 202427.08m1.49%
Victory Capital Management, Inc. (Investment Management)as of 31 Jan 202414.55m0.80%
Goldman Sachs Asset Management LPas of 02 May 202414.44m0.80%
American Century Investment Management, Inc.as of 04 Apr 202413.31m0.73%
Allianz Global Investors GmbHas of 31 Dec 202312.20m0.67%
Norges Bank Investment Managementas of 31 Dec 202311.37m0.63%
China Universal Asset Management Co., Ltd.as of 30 Jun 202311.09m0.61%
BlackRock Fund Advisorsas of 04 Apr 202410.36m0.57%
Bosera Asset Management Co., Ltd.as of 31 Dec 20227.79m0.43%
More ▼
Data from 31 Dec 2023 - 02 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.